Fred Aslan
Seminars
Thursday 4th December 2025
Panel Discussion: Discussing the Latest on the Need for Lymphodepletion in Cell Therapies to Improve Patient Access & Limit Therapeutic Side Effects
9:00 am
- Identify why lymphodepletion has been used in autoimmune cell therapies
- Examine the impact of lymphodepletion on patient recruitment and accessibility
- Consider the advantages and opportunities to remove preconditioning from therapies
Wednesday 3rd December 2025
Industry Leaders Fireside Chat: What’s Happened in the Last Year & Where is the Field Headed Next?
8:40 am
- Examining the evolution of the autoimmune cell therapy field over the last year
- Discussing progress across autologous, allogeneic, NK and in vivo modalities to uncover development strategies
- Considering indication selection strategies and the potential for indication diversification beyond lupus
- Exploring the future of the field to effectively scale and commercialise safe, durable therapies
Wednesday 3rd December 2025
Could Artiva’s NK cells drive cell therapy-like activity with biologics-like ease of use?
10:00 am
- Highlight the rationale and potential advantages of utilizing a non-genetically modified NK cell therapy in combination with monoclonal antibodies in autoimmune diseases
- Explore clinical data demonstrating that NK cell therapies can drive deep B-cell depletion in autoimmune disease while avoiding side effects inherent in CAR-T and TCE therapies
- Highlight a framework for selecting indications for different cell therapies based on their potential target product profile
Wednesday 3rd December 2025
Chair’s Opening Remarks
8:30 am
Thursday 4th December 2025
Chair’s Opening Remarks
8:55 am
Wednesday 3rd December 2025
Chair’s Closing Remarks & End of Conference Day One
5:00 pm
Thursday 4th December 2025
Chair’s Closing Remarks & End of Conference
4:15 pm
